Chrysos Corp Just Posted Record Numbers. Here’s What Actually Matters.
Chrysos Corporation processed 1.36 million samples in a single month — October 2026 — a company record, per its trading update ahead of the November 25 AGM. That’s a real operational milestone, not marketing fluff. Volume in a services business is the closest thing to ground truth you’ll get. But before anyone gets misty-eyed, let’s look at what the numbers actually say, and what they conveniently leave out.
Revenue for July through October came in at A$36.7 million ($24.5 million), up 27% versus the prior comparable period. The breakdown matters more than the headline: A$22.6 million from “Minimum Monthly Assay Payments,” A$13.7 million from “Additional Assay Charges,” and a rounding-error A$300,000 in other revenue.
Here’s what this really means: roughly 62% of revenue is contractual floor — money that shows up whether the machine is working hard or barely working at all. That’s the model’s backbone, and it’s genuinely a decent one. The remaining 38% is variable, tied to sample throughput. Management is quick to highlight that variable revenue has grown from 26% to 38% of the mix as evidence of operating leverage. Fair. It also means the business is becoming more cyclical, not less. When gold exploration budgets get cut — and they always get cut, usually at the worst possible time — that variable slice is what evaporates first. Management will tell you the model “works throughout the mining cycle.” They always say that. Ask them again during the next downturn.
Sample volumes hit 4.9 million for the July–October window, up 43% year over year. Volume growing faster than revenue is worth pausing on. It suggests pricing per sample is compressing, or the mix is shifting toward lower-value contracts. Could be deliberate — land-grab strategy in a young market. Could also be competitive pressure quietly eroding economics. The company doesn’t say, and that silence is itself information. Watch revenue per sample in the next update.
The technology itself, PhotonAssay, came out of CSIRO and replaces traditional fire assay — the centuries-old lead-based process — with a non-destructive, chemical-free analysis of larger sample volumes, results in as little as two minutes. No acids, no lead smelting, no hazardous waste, materially lower CO2 emissions. On the merits, this is a legitimate improvement, not vaporware. Fire assay is dirty, slow, and sample-size constrained; photon assay addresses all three. There’s a reason the majors’ labs keep signing.
And sign they do. Fifteen lease agreements so far in FY27, including eleven since the August update, bringing total contracted units to 973. The recent signings: two direct-to-miner deals, four units with SGS (one mine-site), four with ALS, and one with Alfred H Knight. Deployed units so far this financial year: six, with another six mid-deployment — Bureau Veritas in Kalgoorlie, ALS in Rouyn-Noranda and Surrey in Canada, Aurenne at Mt Ida, and MSA units in Suriname and Ivory Coast. The deployed fleet now sits at 51 units across five continents.
Now here’s the number that deserves a skeptical squint: 973 units contracted, 51 deployed. That’s a contract-to-deployment gap of roughly 19-to-1. Management frames it as a “clear pathway” to 90 deployed units by end of FY29. Maybe. But a signed lease is not revenue, and it certainly isn’t cash flow. Some of those agreements are surely framework deals with the big labs — SGS, ALS, Bureau Veritas — which commit to volumes that depend on customer demand materializing. If miners don’t adopt at the expected pace, those contracts sit unfulfilled and the deployment timeline stretches. This isn’t the first time we’ve seen a company parade a contract backlog that converts slower than the slide deck implies. The honest metric to track quarter over quarter is deployed units and utilization, not signatures.
That said, what management does disclose on utilization is encouraging: fleet availability above 90% on average through July–October, with many units running at high utilization. For capital equipment in remote mining jurisdictions — Suriname, Ivory Coast, the West Australian goldfields — that’s not trivial. Downtime is the silent killer of services economics in this industry, and 90%+ availability suggests the hardware is proven, not just the pitch.
The bull case, stripped of gloss: a genuinely differentiated technology with regulatory and environmental tailwinds, a sticky annuity-style revenue base, anchor customers who are the largest assay labs on the planet, and operating leverage that’s starting to show. The bear case: valuation presumably pricing in flawless execution of a deployment schedule measured in years, revenue per sample trending the wrong way, and 95% of the contracted fleet still theoretical.
My take, for what it’s worth after a few decades of watching “clear pathways” turn into cul-de-sacs: the technology is real and the revenue model is sound, but the gap between contracted and deployed is where this story will be won or lost. If you own it, track three numbers every quarter — deployed units, variable revenue percentage, and availability. If deployed units stall while contracts keep growing, you’re holding a press release, not a business. If utilization holds above 90% while the fleet doubles, the thesis is intact.
Gold prices are doing this company a favor right now — high bullion prices drive drilling and mine-site activity, which drives sample volumes. That tailwind is borrowed, not owned. When the gold cycle turns, the 62% minimum payments will hold the floor. The question is whether the market’s multiple survives the variable half falling back to 26% of revenue.
Nothing here smells fraudulent. It smells like a good business in year three of a ten-year build-out, being marketed like it’s year eight. Size your position accordingly.

